Trends in the Therapeutic Drug Delivery System for the Management of Glaucoma: A Review


Authors : Sneha Ann John; Dr.Gopinath E; Dr.Vineeth Chandy

Volume/Issue : Volume 6 - 2021, Issue 7 - July

Google Scholar : http://bitly.ws/9nMw

Scribd : https://bit.ly/3iabwIg

Glaucoma is the most prevalent neurodegenerative disorder of the eye. It is often called “silent thief of vision” as the symptoms gradually develop and is identified in the later stage of disease that leads to serious irreparable vision impairment. Current trends in the treatment primarily aims at reducing the IOP through pharmacological agents, laser therapy and surgery. Less invasive topical regimens are the most preferred treatment option opted by the patients. Although, these topical therapies are highly preferred and efficacious the downsides of this traditional method involves poor patient compliance and low adherence to prescription. Novel ocular drug delivery platforms offer targeted drug delivery in addition to good therapeutic potential and is independent of patient administration. The role of the innovative drug delivery systems available should be emphasized. This review aims to highlight the recent trends and challenges in ocular drug delivery systems that are commercially available today and to be approved in the future overcoming the limitations of the customary traditional method. Multiple research works have shown sustained drug delivery system that are non-invasive, provide better patient compliance and can benefit the patient and physician alike.

Keywords : Glaucoma, Targeted Drug Delivery, Sustained Release, Compliance, Adherence

CALL FOR PAPERS


Paper Submission Last Date
30 - November - 2021

Paper Review Notification
In 1-2 Days

Paper Publishing
In 2-3 Days

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe